Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)

Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)

Hypothesis:

Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a period of 18 months has anti-inflammatory and neuroprotective properties in patients with relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical examination (EDSS and MSFC).

This multicentric, national study investigates the efficacy and safety of EGCG in patients with relapsing-remitting multiple sclerosis.

Inclusion Criteria:

• male and female subjects age 18 to 60
• relapsing-remitting course of MS
• stable treatment with glatiramer acetate at least 6 months prior to inclusion

Exclusion Criteria:

• primary or secondary progressive forms of MS
• clinically relevant heart, lung, liver, kidney diseases
• regular hepatotoxic co-medication
• drug addiction
• alcohol abuse